Clinical trials: Artery Disease, Peripheral
Critical Limb Ischemia
A Safety and Tolerability Study of RJX Drug Product in Healthy Participants
Designed as a single center, two-part, double-blind, placebo-controlled, randomized study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of RJX in healthy participants.
- Trial name
- NCT03680105
- Testing
- RJX
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Reven Pharmaceuticals, Inc.
Peripheral Artery Disease (PAD)
Α Pre CE-Marking Study Using the Rontis Drug Coated Balloon for Treatment of Lesions in Femoropopliteal Arteries
The Rontis Drug Coated - Peripheral Balloon Catheter is intended for PTA procedure on atherosclerotically stenotic or obstructed vessels and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis…
- Trial name
- NCT04821388
- Testing
- Rontis DCB
- Where
- 5 sites in Greece
- Volunteers
- 30 people
- Sponsor
- Rontis Hellas SA
Critical Limb Ischemia
Retrograde Recanalization of Infrainguinal Arterial Occlusive Disease.
The spectrum of lower extremity peripheral arterial disease (PAD) ranges from exhibiting no symptoms to limb threatening gangrene.
- Trial name
- NCT04974905
- Testing
- retrograde access for re-canalization of infra-inguinal arterial occlusive disease
- Volunteers
- 40 people
- Sponsor
- Sohag University
Renal Impairment, Limb Ischemia, Critical
Ultra-low Dose Contrast for Endovascular Procedures
The purpose of this protocol is to study the safety and feasibility of using ultra-low dose iodinated contrast agent for infrainguinal endovascular revascularization procedures in patients with chronic limb-threatening lower limb…
- Trial name
- ULTRA-LOW (NCT06835127)
- Testing
- Infrainguinal peripheral endovascular revascularization
- Where
- Greece
- Volunteers
- 18 people
- Sponsor
- Attikon Hospital
Peripheral Arterial Occlusive Disease, Femoropopliteal Artery Occlusion
FRAMED Infrainguinal Venous Bypass Versus Conventional Autologous Bypass Trial
The purpose of this clinical trial is to analyze patency after autologous infrainguinal bypass surgery in patients receiving a venous conduit versus a covered venous conduit.
- Conditions
- Peripheral Arterial Occlusive Disease, Femoropopliteal Artery Occlusion, Femoropopliteal Stenosis, Critical Limb-Threatening Ischemia
- Trial name
- Framed IVB (NCT06082466)
- Testing
- FRAMED Infrainguinal Venous Bypass, Conventional Autologous Bypass
- Where
- Austria
- Volunteers
- 110 people
- Sponsor
- Paracelsus Medical University
Peripheral Arterial Disease
Evaluating Plaque Photoablation Using an Excimer Laser in Patients With Lower Extremity Vascular Disease
The purpose of this study is to evaluate the safety and efficacy of an excimer laser in the treatment of patients with lower extremity vascular disease with chronic total occlusions.
- Trial name
- NCT02653456
- Testing
- RA-308 Excimer Laser and DABRA Catheter
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- Ra Medical Systems
Peripheral Arterial Disease
PAD Awareness Study
Peripheral arterial disease (PAD) is one of the most common cardiovascular diseases in developed countries [1] and is an emerging problem in developing countries [2, 3].
- Trial name
- NCT05552079
- Testing
- No intervention
- Where
- Hong Kong
- Volunteers
- 1,000 people
- Sponsor
- Chinese University of Hong Kong
Peripheral Arterial Disease
Exoskeleton Footwear to Improve Walking
The purpose of this study is to determine the best assistance level of an exoskeleton footwear (EF) that can assist walking for people older than 40 with and without peripheral artery disease (PAD).
- Trial name
- NCT04337554
- Testing
- Exoskeleton footwear
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Vascular Diseases, Diabetes
Optimized Strategy for Diabetic Patients With Critical Limb Ischemia(Part II) (DCLI-II)
The purpose of this trial is to find out the appropriate way to treat DM patients with critical limb ischemia. This trial includes two parts.
- Trial name
- DCLI-II (NCT01173094)
- Testing
- Percutaneous Transluminal Angioplasty, below-knee arterial bypass
- Where
- 3 sites in China
- Volunteers
- 130 people
- Sponsor
- Peking Union Medical College Hospital
PAD - Peripheral Arterial Disease
Home-based Walking Program With Smart Devices
Intermittent claudication (IC), the most common manifestation of peripheral artery disease (PAD), represents not only a significant detriment in quality of life, but also an increased risk for atherosclerotic cardiovascular…
- Trial name
- NCT04113057
- Testing
- Remote Coaching
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Dallas VA Medical Center
Peripheral Vascular Diseases
Mirror Trial - Follow-Up Management of Peripheral Arterial Intervention With Clopidogrel
The Mirror Study is a randomized, double-blinded mono-centre trial the access the periinterventinal and postinterventional administration of clopidogrel in patients with peripheral vascular disease.
- Trial name
- NCT00163267
- Testing
- clopidogrel
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- University Hospital Tuebingen
Mild Cognitive Impairment, Dementia
Remote Ischemic Conditioning of the Human Brain in Dementia Patients
The study investigates the incidence of remote ischemic conditioning in mild cognitive impairment and dementia patients
- Conditions
- Mild Cognitive Impairment, Dementia, Intermittent Claudication
- Trial name
- RICBDE (NCT04168021)
- Testing
- Leg ischemia
- Volunteers
- 90 people
- Sponsor
- Aristotle University Of Thessaloniki
Peripheral Arterial Disease (PAD), Claudication, Intermittent
Expression of GLP1 Receptor on Peripheral Blood Mononuclear Cells in Advanced Peripheral Artery Disease: Paving the Way for GLP1R Agonists Treatment in Chronic Limb Threatening Ischemia
The goal of this observational study is to learn whether activation of the GLP-1 receptor could represent a therapeutic target by characterizing its expression and associated inflammatory mechanisms in patients with peripheral…
- Conditions
- Peripheral Arterial Disease (PAD), Claudication, Intermittent, Chronic Limb-Threatening Ischemia
- Trial name
- EXCEL-CLTI (NCT07340112)
- Testing
- Analysis of GLP-1 receptor expression
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Strasbourg, France
Common Iliac Artery Occlusive Disease, External Iliac Artery Occlusive Disease
Evaluation of the GORE® VIABAHN® BALLOON EXPANDABLE ENDOPROSTHESIS (VIABAHN BX)
The primary objective of the VBX13-05 clinical study is to evaluate the safety and efficacy of VIABAHN BX for the treatment of arterial occlusive disease in patients with de novo or restenotic lesions in the common and/or…
- Conditions
- Common Iliac Artery Occlusive Disease, External Iliac Artery Occlusive Disease, Peripheral Arterial Disease
- Trial name
- NCT01961167
- Testing
- Stenting of common and/or external iliacs
- Where
- New Zealand
- Volunteers
- 27 people
- Sponsor
- W.L.Gore & Associates
Coronary Artery Disease (CAD), Peripheral Arterial Disease (PAD)
Rivaroxaban Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk
Registry to describe the impact in terms of effectiveness and safety of the combination treatment of rivaroxaban 2.5 mg twice daily with aspirin on clinical outcomes and practices in a real-life Dutch patient population that are…
- Trial name
- NCT04753372
- Testing
- Rivaroxaban 2.5 MG [Xarelto]
- Where
- 12 sites in Netherlands
- Volunteers
- 645 people
- Sponsor
- Maatschap Cardiologie Zwolle
Peripheral Arterial Disease, Intermittent Claudication
Motivating Structured Walking Activity in Intermittent Claudication
Peripheral arterial disease can cause leg pain or discomfort (called intermittent claudication (IC)), which limits the ability to walk and carry out everyday activities.
- Conditions
- Peripheral Arterial Disease, Intermittent Claudication, Peripheral Vascular Disease
- Trial name
- MOSAIC (NCT03238222)
- Testing
- MOSAIC
- Where
- 9 sites in United Kingdom
- Volunteers
- 192 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Peripheral Arterial Disease
TiVi Evaluation of Microcirculatory Reactivity of the Skin to Galvanic Stimulation: Effect of Aspirin
Prospective interventional study. The aim is to analyze the effect of usual ongoing treatments over microvascular cutaneous response to galvanic current applications (CIV: current induced vasodilatation) with tissue vitality…
- Trial name
- PIRAAT (NCT03357367)
- Testing
- TiVi system
- Where
- France
- Volunteers
- 830 people
- Sponsor
- University Hospital, Angers
Atherosclerotic Peripheral Arterial Disease, Hemoglobin A1c Protein, Human
Novel Risk Factors and Localization of Peripheral Arterial Disease
Background: .Atherosclerotic peripheral arterial disease (PAD) is associated with a high risk of mortality, coronary events and stroke. The distal localization is frequently associated with amputation.
- Conditions
- Atherosclerotic Peripheral Arterial Disease, Hemoglobin A1c Protein, Human, Guadeloupe
- Trial name
- GWADAOMI (NCT07233356)
- Where
- Guadeloupe
- Volunteers
- 123 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Vascular Diseases, Peripheral Artery Disease
RECCORD (Recording Courses of Vascular Diseases) Registry
The RECording COurses of vasculaR Diseases registry (RECCORD registry) is an observational, prospective, multicentre, all-comers registry platform.
- Conditions
- Vascular Diseases, Peripheral Artery Disease, Claudication, Critical Limb Ischemia
- Trial name
- RECCORD (NCT03448029)
- Where
- Germany
- Volunteers
- 6,000 people
- Sponsor
- Deutsche Gesellschaft für Angiologie, Gesellschaft für Gefäßmedizin e.V.
End Stage Kidney Disease
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo.
- Trial name
- POSIBIL6ESKD (NCT05485961)
- Testing
- CSL300
- Where
- 566 sites in United States, Argentina and 33 more
- Volunteers
- 3,110 people
- Sponsor
- CSL Behring
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.